• Events
    • EURETINA 2022 Hamburg
      • Sustainability Plan
      • Registration Information
      • Main Programme
      • Satellite Symposia
      • Exhibitors
      • Hotel Bookings
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • 2022 Hamburg Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • EURETINA 2022 Hamburg
      • Sustainability Plan
      • Registration Information
      • Main Programme
      • Satellite Symposia
      • Exhibitors
      • Hotel Bookings
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • 2022 Hamburg Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
  • July 8, 2020
  • Author: EURETINA Brief

Novartis and Alcon settled bribery fines of $347M related to Lucentis drug and artificial lenses

A Reuters and Washington Post article have confirmed that Novartis AG, and a former subsidiary (Alcon), have agreed to pay $347 million fines to “resolve allegations that the companies ran schemes to bribe public hospitals and clinics in Greece, Vietnam and South Korea”. Investigations from the U.S. Department of Justice and the U.S. Securities and Exchange Commission (SEC) reported alleged criminal and civil violations of the Foreign Corrupt Practices Act.  The allegations included corrupt payments for prescriptions for Lucentis and corrupt payments related to artificial lenses.  Mr. Brian A. Benczkowski, Assistant Attorney General of the US Justice Department’s Criminal Division stated that “Novartis AG’s subsidiaries profited from bribes that induced medical professionals, hospitals, and clinics to prescribe Novartis-branded pharmaceuticals and use Alcon surgical products, and they falsified their books and records to conceal those bribes. The resolutions announced today reflect the paramount importance of effective compliance programs and the department’s commitment to holding companies accountable when they fall short.”

 

In follow up to the settlement, U.S. Attorney Craig Carpenito for the District of New Jersey stated “the agreement we’re announcing today shows that there will be a heavy price paid by companies that violate our laws, whether at home or overseas”.  Novartis’ CEO, Dr. Vasant Narasimhan, who joined the company in 2005, stated that the settlement fine of $347M will now focus on putting behind legacy issues.  Novartis General Counsel, Shannon Thyme Klinger, Chief Ethics, Risk and Compliance Officer stated that “all outstanding FCPA (Foreign Corrupt Practices Act) investigations into the company are now closed”.  Novartis’ market capitalisation, as of today’s writing, is valued $200,000,000,000.  The Swiss company had booked FY2019 sales of $47,455,000,000, of which Lucentis sales in the same period (FY2019) were $2,086,000,000.

 

Reporting on the bribery allegations into Novartis, the Washington Post stated that Greek prosecutors in 2018 sent a report to parliament alleging that Novartis employees had paid tens of millions of euros in bribes to doctors and politicians to fix the price of its drugs at artificially high prices”.  The reporting based in Greece, involved a scheme “to bribe employees of Greek state-owned and state-controlled hospitals and clinics by sponsoring their travel to international medical conferences, including events held in the U.S.”. Novartis agreed to pay a criminal penalty of $225 million, while its parent company agreed to pay more than $112 million in disgorgement and interest, representing the amount of illicit profits.  The companies were also accused of falsifying books and records to conceal the payments, also reported from the New York Times.

 

 

PrevPrevious
NextNext

You might also like

World Retina Day: Italian Retina Society – The Choroid in Retinal Diseases: a tribute to Gerard “Jerry” Lutty

Read More

Subspecialty Session: Tumours III: Masquarading syndromes and lymfoma

Read More

Speakers’ Corner 7: Mixed Session

Read More

Meet the Keynote Speakers

Euretina Lecture with Sobha Sivaprasad
Opthalmologica Lecture with Enrico Borrelli
Ophthalmologica Lecture with Enrico Borrelli
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Kreissig Award Lecture with Hiroko Terasaki
Kreissig Award Lecture with Hiroko Terasaki

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2022 All rights reserved

  • Events
    • EURETINA 2022 Hamburg
      • Sustainability Plan
      • Registration Information
      • Main Programme
      • Satellite Symposia
      • Exhibitors
      • Hotel Bookings
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • 2022 Hamburg Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login